Startups
NeuMoDx™ Molecular Systems are a family of scalable platforms that integrate the entire molecular diagnostic process from "sample to result." Learn more.
Overview
Location
United States, Michigan, Ann Arbor
Phone
+1 888-301-6639
Total raised
$28M
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 17, 2021 | Baird Capital | bairdcapital.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 9, 2011 | Series A round | $7M |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 20, 2019 | BD sues NeuMoDx over patents for diagnostic device | Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2... |
| Nov 18, 2014 | With Midwest Startup Investing at an All-Time High, Baird Capital Closes a $180 M Fourth Fund | In late October, TechCrunch reported that the Midwest is on track for its strongest year in startup investing ever. Today, that track was strengthened with the announcement of the closing of Baird Capital's $185 million Fourth Fund. Th... |
| Nov 18, 2014 | Baird Capital Announces Close of $185M Venture Capital Fund IV | CHICAGO, Nov. 18, 2014 – Baird Capital, the direct private investment arm of Robert W. Baird & Co. (Baird), announced the final close of its fourth Venture Capital fund with a total of $185 million in committed capital, exceeding its in... |
| Apr 1, 2014 | Baird Capital Co-Leads $21 Million Series B Financing for NeuMoDx Molecular Inc. | Baird Capital co-led a $21 million Series B financing in NeuMoDx Molecular Inc., a diagnostics company developing a new platform for high-efficiency, low-cost molecular testing. “Molecular diagnostic testing continues to be an attractive in... |
| Apr 1, 2014 | NeuMoDx Molecular Raises $21M in Series B Financing | NeuMoDx Molecular, Inc., an Ann Arbor, MI-based diagnostics company developing a new platform for high throughput, low cost molecular testing, raised $21m in Series B financing. The round was led by Pfizer Ventures with participation from B... |
| May 9, 2011 | Molecular Imaging Research Secures $7m Series A Financing, Co-Led By Baird Venture Partners And Arcus Ventures | ANN ARBOR, Mich., May 9, 2011 |
Reviews 0
FAQ about NeuMoDx
How much funding has NeuMoDx raised?
NeuMoDx has raised $28M in total across 2 funding rounds.
What funding rounds has NeuMoDx raised?
Parsers VC lists 2 funding rounds of NeuMoDx, among them a Series A round of $7M on May 9, 2011.
Who has invested in NeuMoDx?
Parsers VC lists 2 investors of NeuMoDx, among them Baird Capital.
What has the press written about NeuMoDx?
Parsers VC has collected 7 articles mentioning NeuMoDx, among them “BD sues NeuMoDx over patents for diagnostic device” (Jun 20, 2019) and “With Midwest Startup Investing at an All-Time High, Baird Capital Closes a $180 M Fourth Fund” (Nov 18, 2014).
Is NeuMoDx still active?
Yes, NeuMoDx is active; its latest activity on Parsers VC dates from Jul 17, 2021.